Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAtlantic Lithium Regulatory News (ALL)

Share Price Information for Atlantic Lithium (ALL)

Share Price is delayed by 15 minutes
Get Live Data
16.30    -0.15 (-0.91%)
Bid:
16.30
Ask:
16.35
Spread: 0.05 (0.307%)
Market Cap: £130.65m
ALL Live PriceLast checked at - London Stock Exchange

Intraday Atlantic Lithium Share Chart

Trading Update

24 Jun 2013 07:00

RNS Number : 6463H
Allocate Software PLC
24 June 2013
Β 

ο»Ώ

24 June 2013

Β 

ALLOCATE SOFTWARE PLC

("Allocate" or "the Company")

Β 

Full Year Trading Update

Β 

Allocate Software (AIM: ALL), the leading provider of workforce and compliance optimisation solutions, announces an update on trading for its financial year ended 31 May 2013. The Company's audited results will be announced in the week commencing 22 July 2013.

Β 

Overview

Β 

Allocate delivered a very strong second half performance with full year results in line with market expectations for both revenue and EBITA. The Company's cash performance has materially exceeded analysts' expectations due to the continuing transition in the Company's business model to one based more on recurring revenues and due to improvements in working capital.

Β 

Business

Β 

The Healthcare business achieved another successful year securing a significant number of agreements for both new products and new customers.

Β 

UK Healthcare bookings are ahead of revenue because the number of recurring orders secured has been higher than anticipated. The financial effect of this is that cash, deferred revenue and contracted, unbilled orders in hand are higher than anticipated. As a result, this will increase the visibility and predictability of future years' revenue streams.

Β 

The number of new HealthRoster customers secured by the Company was slightly fewer than the previous financial year but met management's expectations for the second half of the current year. Several of the new customers secured were competitor displacements and HealthRoster renewals continued at the previously recorded 100% renewal rate.

Β 

The Allocate Cloud, launched in July, has exceeded management original plans with new customers entering agreements in addition to existing customers who have already licensed the software, committing to the Cloud service. A further positive impact of this performance is on cash flow, as noted above.

Β 

Sales of the Medics products enjoyed a good year with a number of new customers signing contracts and a high renewal rate of annual subscriptions. Multiyear renewals have been secured with substantially more customers than anticipated demonstrating high levels of customer satisfaction. A further beneficial impact of the multiyear renewals is on cash flow, as noted above.

Β 

The migration from HealthRoster V9 to V10 continues in line with management plans. Customers that have migrated are located primarily in the UK, along with customers in the USA and Australia.

Β 

The Defence business had a productive year securing a major contract with Royal Australian Airforce as well as securing a series of important professional services contract extensions.

Β 

The Maritime business had a successful year securing a new offshore services customer in addition to closing a number of important follow on licence and services contract extensions.

Β 

Ian Bowles, Chief Executive Officer of Allocate commented: "2012 was a very important year for Allocate. We launched HealthRoster V10, our most important product for many years and we launched the Allocate Cloud, a completely new HealthRoster service that has been extremely well received by our customers and prospects. Sales of our Medics portfolio of applications exceeded management plans and we continued to secure our 100% renewal rate on HealthRoster. Both the Defence and Maritime businesses again performed solidly.

Β 

"At the same time as delivering revenue in line with expectations we continued our transition to a business with higher recurring and deferred revenues. Although revenue growth has been masked by both a large order in the prior year and the move to higher recurring and deferred revenues, billings and cash show more significant growth and more fairly reflect the true underlying progress that Allocate has achieved this year.

Β 

"We remain well placed to support the broader healthcare market in general and specifically the NHS in its goals of improving patient care whilst driving improvements in efficiency."

Β 

Enquiries:

Β 

Allocate Software plc

Ian Bowles - Chief Executive Officer

Chris Gale - Chief Financial Officer

Martin Jeffries - Marketing Director

Β 

Tel: +44 (0) 20 7355 5555

Numis Securities

Nominated adviser - Michael Meade / Simon Willis/ Richard Thomas

Corporate Broking - James Black

Β 

Tel: +44 (0) 20 7260 1000

Gable Communications

Justine James / John Bick

Β 

Tel: +44 (0) 20 7193 7463

M: +44 (0) 7525 324431

Β 

About Allocate Software plc

Allocate Software plc is the leading workforce optimisation software applications provider for world-wide organisations with large, multi-skilled workforces. With a blue chip client base spanning the public and private sector, its key vertical markets include: Healthcare and Defence.

Β 

At the core of the business is Allocate's workforce optimisation software, which organisations use to deploy the right people with the right skills, to the right place at the right time. Headquartered in London, Allocate provides services and support to its increasing international customer base through regional offices in the UK, Sweden, USA, Australia and Malaysia.

Β 

Allocate is quoted on the London Stock Exchange (AIM: ALL). For further information please visit www.allocatesoftware.com.

Β 

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
TSTUAVBRONANUAR
Date   Source Headline
3rd Mar 20091:49 pmRNSAward of Contracts
4th Feb 20091:25 pmRNSHolding(s) in Company
21st Jan 20097:00 amRNSInterim Results
15th Jan 200911:58 amRNSHolding(s) in Company
19th Dec 200810:58 amRNSResult of AGM
10th Dec 20087:00 amRNSAcquisition of Baum Hart & Partners
1st Dec 20087:00 amRNSAward of Contracts
21st Nov 20084:32 pmRNSAnnual Report and Accounts
28th Oct 20087:00 amRNSHolding(s) in Company
1st Oct 20086:16 pmRNSHolding(s) in Company
1st Oct 20083:10 pmRNSHolding(s) in Company
17th Sep 20084:32 pmRNSHolding(s) in Company
10th Sep 20083:44 pmRNSHolding(s) in Company
8th Sep 20087:00 amRNSAward of contracts
28th Jul 20087:00 amRNSFinal Results
15th Jul 20085:43 pmRNSHolding(s) in Company
30th Jun 20087:00 amRNSDirectorate Change
10th Jun 20087:00 amRNSAward of Contract
2nd Jun 20087:00 amRNSAward of Contracts
27th May 20089:34 amRNSDirector/PDMR Shareholding
22nd May 20087:00 amRNSAward of Contract
6th May 20087:02 amRNSAward of Directors' Options
2nd May 20087:00 amRNSHolding(s) in Company
7th Apr 20087:01 amRNSAcquisition
4th Apr 20087:01 amRNSTrading Statement
26th Mar 20088:00 amRNSAward of Contract
17th Mar 20087:00 amRNSAward of Contract
10th Mar 20087:00 amRNSAward of Contract
4th Mar 20087:00 amRNSAward of Contract
28th Feb 20089:01 amRNSExercise of Share Options
26th Feb 20087:00 amRNSAward of Contract
21st Feb 20087:00 amRNSAward of Contract
6th Feb 20087:01 amRNSInterim Results
4th Feb 20087:01 amRNSAward of Contract
31st Jan 20087:00 amRNSAward of Contract
22nd Jan 20087:00 amRNSAward of Contract
18th Jan 20087:01 amRNSAward of Contract
17th Jan 20087:00 amRNSHolding(s) in Company
15th Jan 200812:06 pmRNSHolding(s) in Company
4th Jan 20089:38 amRNSTotal Voting Rights
4th Jan 20087:00 amRNSAward of Contract
4th Jan 20087:00 amRNSAward of Contract
3rd Jan 20088:46 amRNSAward of Contract
20th Dec 20077:01 amRNSAGM Statement
12th Dec 200711:13 amRNSHolding(s) in Company
11th Dec 20077:00 amRNSCorrection: Holdings in Co.
10th Dec 20074:43 pmRNSHolding(s) in Company
3rd Dec 200711:30 amRNSDirector/PDMR Shareholding
29th Nov 20077:01 amRNSCirc re. contract extension
21st Nov 20077:01 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.